Healthcare Tech Firm and Leading University to Join Forces
Source: Streetwise Reports  (9/7/24)
The parties intend to develop artificial intelligence-backed solutions to a problem in healthcare, for expanded use throughout and beyond the United Kingdom. Find out why one analyst is bullish on this company and its proprietary platform. More >

Mass. Biopharma Reports Positive Data and Announces New Program
Source: Dr. David Nierengarten  (9/6/24)
Wedbush analysts noted that they would be buyers ahead of Vor Biopharma Inc.'s (VOR:NASDAQ) planned regulatory updates and likely further data readouts. More >

Pharma Co. Enrolls First Patient in Trial
Source: Dr. Joseph Pantginis  (9/5/24)
Rigel Pharmaceuticals (RIGL:NASDAQ) recently announced the enrollment of the first patient in a Phase 1b/2 trial assessing decitabine and venetoclax in combination with Rezlidhia in mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AML), according to an H.C. Wainwright & Co. research note, which rated the stock a Buy. More >

Florida Biotech Completes Enrollment in 'Pivotal' Drug Trial
Source: Streetwise Reports  (8/16/24)
Florida-based Cyclo Therapeutics Inc. (CYTH:NASDAQ) says it has completed enrollment in its "pivotal" TransportNPC trial of Niiemann-Pick Type C1, a rare progressive genetic disorder. Find out why analysts are recommending the stock. More >

Long Term Care Co.'s Target Price Raised
Source: Dr. Douglas Loe  (8/14/24)
Leede Financial Inc. recently raised the target price on Extendicare Inc. (EXE:TSX) based on FQ24 financial results. More >

Promising Clinical Data and Strategic Partnerships Propel Oncology Co.
Source: Streetwise Reports  (8/9/24)
Elevation Oncology Inc.(ELEV:NASDAQ) reported its second-quarter 2024 financial results on August 6, highlighting significant progress in its clinical trials and ongoing business achievements. Read on to see why three experts believe this stock is a Buy. More >

AI Healthcare Co. Signs Partnership With Large Regional Health Plan
Source: Dr. Jonathan Aschoff  (8/9/24)
Ontrak Inc. (NASDAQ: OTRK) announced it had signed a two-year strategic partnership with a large, northeast regional health plan focused on the plan's New York State members. This development comes as the company continues to rebuild its client base following a significant customer loss in Q1 2024, noted a Roth MKM research note. More >

Boston Biotech Reports Promising Interim Data
Source: Dr. Swayampakula Ramakanth  (8/7/24)
Interim efficacy data reported for Elevation Oncology Inc.'s (ELEV:NASDAQ) EO-3021 as a monotherapy is competitive and potentially could be superior as a combination therapy, according to an H.C. Wainwright & Co. research note. More >

New Firmware Update Enhances Counter-Drone Capabilities
Source: Streetwise Reports  (8/6/24)
DroneShield Ltd. (DRO:ASX; DRSHF:OTC) has released its latest firmware update for its full range of Radio Frequency (RF) sensors. Read about what this advancement means for the technological power of the company's product line. More >

AI Healthcare Co. Creates AI Pharmacy Assistant
Source: Streetwise Reports  (8/2/24)
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) announced it will roll out a new AI (artificial intelligence) Pharmacy Assistant to support pharmacists. One analyst says the company has positioned itself as a "central go-to resource." More >

Exercised Warrants Show Confidence in AI-Driven Healthcare Innovations
Source: Streetwise Reports  (7/29/24)
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has successfully seen the exercise of nearly 800,000 warrants issued on conversion of special warrants in June for gross proceeds of about CA$500,000. See why one technical analyst rates this stock a Buy as the company solidifies its investor confidence. More >

Analyst Says CA Pharma Underappreciated by Investors
Source: Patrick Trucchio  (7/23/24)
Arrowhead Pharmaceuticals Inc. (ARWR:NASDAQ) recently hosted a webinar going over its pulmonary programs. Read on to see why an H.C. Wainwright & Co. analyst believes the company is underappreciated by investors. More >

Analyst's Target Price for Biotech Massively Higher Than Current Price
Source: Dr. Leland Gershell  (7/22/24)
Oppenheimer & Co. recently put out a report that gave NuCana Plc. (NCNA:NASDAQ) a target price of US$150. The stock is currently trading at US$2.98. Read on to see why the analyst has given the company such a massive target price. More >

Study Shows 93% Cough Suppression With Co.'s Drug
Source: Streetwise Reports  (7/18/24)
Clinical-stage pharmaceutical development company Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGN0:XFRA) announced the drug ifenprodil achieved a 93% reduction in median cough count in an acute guinea pig citric acid challenge study. Find out why one analyst says this stock is headed for a "major bull market." More >

Could This Stock Be the Next Bellus Cough Treatment?
Source: Clive Maund  (7/17/24)
Technical Analyst Clive Maund shares an extensive overview of Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGN0:XFRA) to explain why he believes it is a Strong Buy. More >

LA Biotech Unveils New Patented Nicotinamide Riboside Chloride
Source: Dr. Raghuram Selvaraju  (7/15/24)
"The advent of NIAGEN IV could usher in a powerful new tailwind for revenue growth at ChromaDex Corp. (CDXC:NASDAQ)," noted an H.C. Wainwright & Co. report. More >

Healthcare AI Company Achieves Key Milestones and Secures New Partnerships
Source: Streetwise Reports  (7/11/24)
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has provided a general corporate update, detailing significant progress made through Q1 and Q2 of 2024. Read about what this means for the future of its platform, the Global Library of Medicine (GLM) and future projects. More >

Biopharma Co. Reports Strong FQ224 Results Driven
Source: Dr. Douglas Loe  (7/11/24)
Leede Financial Inc. analyst Dr. Douglas W. Loe wrote he is maintaining his target price and Buy rating on Theratechnologies Inc. (TH:TSX). More >

Texas Biotech Announces Plans for Preclinical Obesity Studies
Source: Dr. Jonathan Aschoff  (7/8/24)
Bio-Path Holdings Inc. (BPTH:NASDAQ) recently announced its progress in its cancer clinical trials and plans to begin preclinical obesity studies, according to a Roth MKM research note. More >

AI Health Stock Heading Higher Expert Says
Source: Clive Maund  (7/2/24)
Technical Analyst Clive Maund gives an update on Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) as he believes "something is going on" and the stock may be heading higher. More >

New Patents and Strategic Partnerships Boost Smart Home Innovation
Source: Streetwise Reports  (7/1/24)
SKYX Platforms Corp. (SKYX:NASDAQ), a leader in smart platform technology, has announced the issuance of six additional patents in the U.S. and internationally, expanding its already robust patent portfolio to over 94 issued and pending patents globally. Find out how these partnerships affect upcoming projects and plans. More >

California Biotech Reports Positive Phase 3 Results
Source: Ed Arce  (6/25/24)
"Along with the significantly lower pill burden compared to other phosphate binders, we believe the superior tolerability may be attributable to OLC's nanoparticle technology," noted an H.C. Wainwright & Co. research note, regarding Unicycive Therapeutics Inc.'s (UNCY:NASDAQ) trial of oxylanthanum carbonate (OLC) for the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients. More >

Major New Contract Marks Significant Milestone for Counter-Drone Tech Co.
Source: Streetwise Reports  (6/24/24)
DroneShield Ltd. (DRO:ASX; DRSHF:OTC) has announced a significant new contract valued at AU$4.7 million from a non-government Swiss international customer. Find out why this is a major milestone for the company. More >

Chicago Alt. Medicine Co. Announces US$50M Share Repurchase Program
Source: Nick Anderson  (6/18/24)
In a Roth MKM research note, analyst Nick Anderson noted that Verano Holdings Corp. (VRNO:CSE; VRNOF:OTCQX) was well-positioned to generate increasing cash flow. More >

Clean Tech Subsidiary Finds Manufacturer for Wound Solution
Source: Streetwise Reports  (6/14/24)
BioLargo Inc. (BLGO:OTCQB) announced that subsidiary Clyra Medical Technologies Inc. has selected a company to support the manufacturing of its medical products, including its surgical wound irrigation solution, Bioclynse. See why one nonprofit group says the rate of healthcare-associated infections has remained high since the pandemic. More >